HO-1 drives the resistance of BRAFV600E mutated melanoma cells against vemurafenib treatment [44] and can directly interact with BRAF protein, leading to the activation of CDK2/cyclin E-dependent induction of cell proliferation [45]. This evidence concerns the gene HMOX1 and melanoma.